Genmab — Juni 2019

[E_L]

it seems they want to build the Dara successor / patent extension? Janssen logical partner, also as they can probably not work on on any CD38 myeloma targets themselves under the current contract

[Sukkeralf]

Probably both life cycle management and maybe a stronger solid tumor candidate - but nice to see a commerciel HexaBody deal. Great

[Solsen]

We have seen hexabody tech. add potency. Very good to se JNJ want to grab the chance to be on board with hexa.

[Helge_LarsenPI-redaktør]

Better late than never.

[Legolas23]

Bert good news !

[Legolas23]

Very

[E_L]

am I reading it correctly that ALL development costs will be for Genmab, until Janssen exercises its option?

[bibob]

God morgen. :-). Dejligt med lidt nyt samarbejde med Jansen. :-). Børsen har ikke opdaget det endnu.

[Plimsoller]

Looks like it E L. If terms and conditions haven’t been completed, that will leave Genmab in a stronger position to negotiation,but until then it
will be expensive and risky.

[Plimsoller]

*to negotiate (damn phone )

[Plimsoller]

There may be some leeway in the tiered royalties (even though that would be strange in my opinion).

[Parasitism]

God morgen

[Plimsoller]

Reading it again I am making no sense. Forget everything I just wrote

[Solsen]

Develop until proff of concept. Phase 1 I belive. Not that expensive.

[StockBull]

ok, so thats the reason Genmab need additional finds

[Sukkeralf]

This could also be an explanation why Genmab needs more money - they could possibly be rather close to a clinical candidate

[StockBull]

funds

[Solsen]

No

[Sukkeralf]

PoC normally is phase IIb

[Sukkeralf]

in cancer maybe just phase II data